Table 1.
Patient demographics
| Variable | N (%) | |
|---|---|---|
| Race/ethnicity | ||
| Non-Latino black | 17 (54.8) | |
| Non-Latino white | 14 (45.2) | |
| Hispanic/Latino | 2 (6.7) | |
| BMI | ||
| Normal (18.5 to < 25) | 5 (16.1) | |
| Overweight (25 to < 30) | 10 (32.3) | |
| Obese (> 30) | 16 (51.6) | |
| Hypertension | 13 (41.9) | |
| Diabetes | 5 (16.1) | |
| Dyslipidemia | 12 (38.7) | |
| Prior radiation therapy | 11 (35.5) | |
| Prior anthracyclines | 17 (54.8) | |
| Prior HER2-targeted therapy | ||
| T | 12 (38.7) | |
| T + P | 17 (54.8) | |
| T-DM1 | 2 (6.4) | |
| Breast cancer stage | ||
| I-III | 18 (58.1) | |
| IV | 13 (41.9) | |
| HER2-targeted therapy received on study | ||
| T | 15 (48.4) | |
| T + P | 14 (45.2) | |
| T-DM1 | 2 (6.4) | |
| Beta blockers on study | Yes | 27 (90) |
| ACEi/ARBs on study | Yes | 21 (70) |
BMI body mass index, T trastuzumab, T + P trastuzumab and pertuzumab, T-DM1 ado-trastuzumab emtansine, ACEi angiotensin converting enzyme (ACE) inhibitors, ARBs angiotensin II receptor blockers